Vemircopan Misses Primary End Point in Phase 2 Trial of Generalized Myasthenia Gravis

Final results from a double-blind, multicenter, phase 2 randomized clinical trial (NCT05218096) showed that treatment with vemircopan, an oral factor D inhibitor, did not significantly improve clinical outcomes compared with placebo in adults with acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR-Ab+ gMG), leading investigators to terminate the study early after the prespecified efficacy threshold was not met.

Despite evidence of pharmacologic target engagement and alternative pathway inhibition, no statistically significant differences were observed across primary or secondary efficacy measures. The findings, published in JAMA Neurology, highlighted ongoing challenges in developing complement-targeted therapies for gMG beyond terminal complement component 5 (C5) inhibition, while raising questions about the therapeutic potential of selectively targeting the complement alternative pathway (AP) in this disease setting.¹

Francesco Saccà, MD, PhD, associate professor of neurology at the University of Naples, and his colleagues enrolled 70 adults with AChR-Ab+ gMG across 60 sites in 8 countries between April 2022 and April 2024. Eligible participants had Myasthenia Gravis Foundation of America class II through IV disease and a Myasthenia Gravis–Activities of Daily Living (MG-ADL) score of at least 5 at baseline. Participants were randomized in a 2:1:2 ratio to receive oral vemircopan 180 mg twice daily, vemircopan 120 mg twice daily, or placebo during an 8-week primary evaluation period.¹

The primary end point was achievement of a 2-point or greater reduction in MG-ADL total score sustained for 4 consecutive weeks without rescue therapy. All told, investigators reported that response rates were similar across treatment groups, with no statistically significant differences between active treatment and placebo. The primary end point was achieved by 57% of patients receiving vemircopan 180 mg, 57% receiving vemircopan 120 mg, and 64% receiving placebo.¹

Secondary efficacy outcomes also failed to demonstrate meaningful benefit. Changes from baseline in MG-ADL scores, Quantitative Myasthenia Gravis (QMG) scores, and Neuro-QoL Fatigue scores at week 8 were not significantly different between vemircopan and placebo groups. Investigators additionally noted that no consistent efficacy trends favoring vemircopan emerged when evaluating higher response thresholds or subgroup analyses.¹

The investigators suggested that an unexpectedly high placebo response may have contributed to the negative outcome. The 64% placebo response rates in the study were “much larger than the approximately 25% anticipated based on previous studies.”¹ The authors also noted that the subjective nature of MG-ADL assessments and repeated weekly testing may have amplified placebo effects.¹

Although efficacy end points were not met, pharmacodynamic analyses confirmed substantial inhibition of alternative pathway activity. Mean serum AP hemolytic activity fell below 10% within 2 hours of treatment initiation in both vemircopan dose groups, with sustained suppression observed predose at week 8 in the 180-mg cohort. However, these biologic effects did not translate into clinically meaningful improvements.¹

Vemircopan was generally associated with a safety profile similar to placebo during the blinded treatment period. Most treatment-emergent adverse events were mild to moderate in severity, with headache, diarrhea, and nausea among the most commonly reported events in the vemircopan groups. No meningococcal infections were observed during the study^.1

Several serious adverse events were reported in the study, including a case of herpes simplex meningitis considered related to treatment in a participant receiving vemircopan 180 mg. In addition, 1 participant who transitioned from placebo to vemircopan during the extension phase died from hepatic failure associated with cytomegalovirus reactivation and concurrent Epstein-Barr virus infection. Investigators stated that these events did not currently appear to represent established risks associated with alternative pathway inhibition.¹

READ MORE: Efgartigimod Gains FDA Approval as First Treatment for Seronegative Forms of Myasthenia Gravis

The study authors acknowledged several limitations, including the relatively small sample size and baseline imbalances across treatment groups involving sex distribution, disease duration, corticosteroid use, and prior exacerbation rates. The inability to stratify randomization by additional baseline characteristics may also have influenced the results.¹

Ultimately, the trial’s failure to meet efficacy thresholds led to early termination of development in this indication. Still, the investigators concluded that alternative pathway inhibition may warrant continued exploration in future clinical studies, particularly given the biologic evidence of complement suppression observed during treatment.

REFERENCES:
1. Saccà F, Gialdini G, Howard JF, et al. Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical Trial. JAMA Neurol. 2026. doi:10.1001/jamaneurol.2026.090